Stocklytics Platform
Asset logo for symbol DAWN
Day One Biopharmaceuticals
DAWN53
$14.32arrow_drop_down3.73%-$0.55
High Growth
Asset logo for symbol DAWN
DAWN53

$14.32

arrow_drop_down3.73%

Performance History

Chart placeholder
Key Stats
Open$15.69
Prev. Close$15.86
EPS-0.97
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range15.22
16.27
52 Week Range9.67
18.07
Ratios
Revenue-
EBITDA Margin %-
EPS-0.97

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Day One Biopharmaceuticals (DAWN)

Day One Biopharmaceuticals, Inc. (DAWN) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for patients with cancer. The company is committed to improving the lives of those affected by cancer through innovative and effective treatment options. With a strong pipeline of potential drugs, Day One Biopharmaceuticals is poised to make a significant impact in the field of oncology.
DAWN stock price history shows that the company has experienced steady growth since its initial public offering. Investors have been attracted to the potential of Day One Biopharmaceuticals' drug candidates and the company's dedication to advancing cancer treatments. The stock has seen significant increases in value over the past year, reflecting investor confidence in the company's future prospects.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jeremy Bender M.B.A., Ph.D.
Headquarters
Brisbane
Employees
124
Exchange
NASDAQ
add Day One Biopharmaceuticals to watchlist

Keep an eye on Day One Biopharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Day One Biopharmaceuticals's (DAWN) price per share?

The current price per share for Day One Biopharmaceuticals (DAWN) is $14.32. The stock has seen a price change of -$0.55 recently, indicating a -3.74% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Day One Biopharmaceuticals (DAWN)?

For Day One Biopharmaceuticals (DAWN), the 52-week high is $18.07, which is 26.19% from the current price. The 52-week low is $9.67, the current price is 48.09% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Day One Biopharmaceuticals (DAWN) a growth stock?

Day One Biopharmaceuticals (DAWN) has shown an average price growth of -3.55% over the past three years. It has received a score of 38 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Day One Biopharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Day One Biopharmaceuticals (DAWN) stock price performance year to date (YTD)?

As of the latest data, Day One Biopharmaceuticals (DAWN) has a year-to-date price change of -1.38%. Over the past month, the stock has experienced a price change of 0.14%. Over the last three months, the change has been 6.79%. Over the past six months, the figure is -10.78%.
help

Is Day One Biopharmaceuticals (DAWN) a profitable company?

Day One Biopharmaceuticals (DAWN) has a net income of -$188.92M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 31.61% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$206.06M. Furthermore, the EBITDA is -$205.5M.
help

What is the market capitalization of Day One Biopharmaceuticals (DAWN)?

Day One Biopharmaceuticals (DAWN) has a market capitalization of $1.44B. The average daily trading volume is 14.5, indicating the stock's liquidity and investor engagement.

News

Global Cancer Antibody Drug Conjugates Market Size Forecast 2030
CANCER
ANTIBODY DRUG CONJUGATES
MARKET SIZE
CLINICAL TRIALS
APPROVALS
Oct 22, 2024

Global Cancer Antibody Drug Conjugates Market Size Forecast 2030

Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
Jun 19, 2024

Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
CLINICAL STUDY
Jun 18, 2024

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Day One Announces Sale of Priority Review Voucher for $108 Million
FINANCING AGREEMENTS
May 30, 2024

Day One Announces Sale of Priority Review Voucher for $108 Million

Day One Reports First Quarter 2024 Financial Results and Corporate Progress
EARNINGS RELEASES AND OPERATING RESULTS
May 6, 2024

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
HEALTH
CLINICAL STUDY
CALENDAR OF EVENTS
Apr 23, 2024

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level